There are many varieties of antibody drug conjugates technologies available and each has its benefits, though no single one is optimal for every payload and antibody. Abzena offers access to a variety of conjugation technologies for evalutation.
ThioBridge™ is Abzena’s proprietary disulfide rebridging linker that delivers more homogeneous ADCs with improved stability. The disulfide bonds are first reduced , but, unlike conjugation using maleimide chemistry, the bond is re-bridged as part of the conjugation process thereby stabilising the tertiary structure of the antibody. Read more >>>
Abzena can engineer unpaired cysteine residues on each heavy chain or exploit interchain disulfide bonds using a engineered cysteines or maleimide or site-specific approach. These approaches allow a DAR of upto 8. Abzena has considerable experience in producing ADCs by these approaches. Read more >>>
Lysine conjugation can involve a one or two step processes. A one-step reaction process can be carried out with a pre-formed linker-drug (usually containing a N-hydroxysuccinimide or other activated ester to react with the antibody) to form the ADC. Read more >>>
Abzena can also perform conjugation using a mixed approach (e.g. Traunt’s reagent), non-natural amino acid incorporation, Enzymatic approaches (e.g. transglutaminase) or Histidine based approach.